NCT06375473 Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
| NCT ID | NCT06375473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2024-04-19 |
| Primary Completion | 2027-04-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2024-04-19 with a primary completion date of 2027-04-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
Eligibility Criteria
Inclusion Criteria: * Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging; * Age ≥18 years old, male or female; * Patients receiving treatment based on irinotecan hydrochloride liposome injection II; * The subjects voluntarily joined the study and signed the informed consent. Exclusion Criteria: * Confirmed pregnant or lactating women; * The researchers determined that other conditions were not suitable for inclusion in the study.
Contact & Investigator
Taiping Zhang, doctor
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital, Beijing, China
Frequently Asked Questions
Who can join the NCT06375473 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06375473 currently recruiting?
Yes, NCT06375473 is actively recruiting participants. Contact the research team at tpingzhang@yahoo.com for enrollment information.
Where is the NCT06375473 trial being conducted?
This trial is being conducted at Hefei, China, Beijing, China, Nanning, China, Zhengzhou, China and 6 additional locations.
Who is sponsoring the NCT06375473 clinical trial?
NCT06375473 is sponsored by Peking Union Medical College Hospital. The principal investigator is Taiping Zhang, doctor at Peking Union Medical College Hospital, Beijing, China. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.